Live
VertexBank of America Names Vertex Pharmaceuticals Top Biotech Pick for 2026 - HarianBasis.coVertexVertex (VRTX) Named Top Biotech Pick for 2026 by BofA - Yahoo FinanceSamsung BiologicsUnionized workers of Samsung Biologics continue strike for 2nd day - ETHRWorld.comCellGenetic variation reveals a homeotic long noncoding RNA that modulates human hematopoietic stem cellsInsilico MedicineInsilico Medicine Advances AI-Designed Pipeline With IBD Data Debut, UAE Milestone and New IPF IND - TipRanks10x Genomics BlogDoes Atera’s New Spatial Biology Platform Change The Bull Case For 10x Genomics (TXG)? - simplywall.stPfizerFDA nod for Arvinas and Pfizer’s Veppanu - The Pharma LetterEndpoints NewsBristol Myers’ pivotal year; Should AI be swinging bigger?; and moreEli LillyWhy Eli Lilly (LLY) Is Up 9.0% After Q1 Beat And Foundayo GLP‑1 Launch - And What's Next - simplywall.stWuXi BiologicsWuXi Biologics Advances Global Sustainability Strategy With 2025 ESG Report - BioPharma APACNovo NordiskFDA Proposal Could Support Novo Nordisk GLP‑1 Exclusivity And Valuation - simplywall.stAmgenBiopharma bites: Novo rebrands Rybelsus as the Ozempic pill, and Amgen trims its pipeline - FirstWord Pharma
FierceBiotech Mar 18, 2026

Beyond seizures: With experimental drug, Stoke aims to restore developmental loss in Dravet syndrome

Beyond seizures: With experimental drug, Stoke aims to restore developmental loss in Dravet syndrome

Original
Body unavailable. Use the original source.